Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review
Therapeutic monoclonal antibodies (mAbs) are standard care for many B-cell haematological cancers. The modes of action for these mAbs include: induction of cancer cell lysis by activating Fcγ-receptors on innate immune cells; opsonising target cells for antibody-dependent cellular cytotoxicity or ph...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1244090/full |
| _version_ | 1797738177647083520 |
|---|---|
| author | Harrison D. Collier-Bain Frankie F. Brown Frankie F. Brown Adam J. Causer Annabelle Emery Rebecca Oliver Rebecca Oliver Sally Moore James Murray James E. Turner James E. Turner John P. Campbell |
| author_facet | Harrison D. Collier-Bain Frankie F. Brown Frankie F. Brown Adam J. Causer Annabelle Emery Rebecca Oliver Rebecca Oliver Sally Moore James Murray James E. Turner James E. Turner John P. Campbell |
| author_sort | Harrison D. Collier-Bain |
| collection | DOAJ |
| description | Therapeutic monoclonal antibodies (mAbs) are standard care for many B-cell haematological cancers. The modes of action for these mAbs include: induction of cancer cell lysis by activating Fcγ-receptors on innate immune cells; opsonising target cells for antibody-dependent cellular cytotoxicity or phagocytosis, and/or triggering the classical complement pathway; the simultaneous binding of cancer cells with T-cells to create an immune synapse and activate perforin-mediated T-cell cytotoxicity against cancer cells; blockade of immune checkpoints to facilitate T-cell cytotoxicity against immunogenic cancer cell clones; and direct delivery of cytotoxic agents via internalisation of mAbs by target cells. While treatment regimens comprising mAb therapy can lead to durable anti-cancer responses, disease relapse is common due to failure of mAb therapy to eradicate minimal residual disease. Factors that limit mAb efficacy include: suboptimal effector cell frequencies, overt immune exhaustion and/or immune anergy, and survival of diffusely spread tumour cells in different stromal niches. In this review, we discuss how immunomodulatory changes arising from exposure to structured bouts of acute exercise might improve mAb treatment efficacy by augmenting (i) antibody-dependent cellular cytotoxicity, (ii) antibody-dependent cellular phagocytosis, (iii) complement-dependent cytotoxicity, (iv) T-cell cytotoxicity, and (v) direct delivery of cytotoxic agents. |
| first_indexed | 2024-03-12T13:39:17Z |
| format | Article |
| id | doaj.art-4fb719a767b54c49a07e03d0de5045f4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T13:39:17Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4fb719a767b54c49a07e03d0de5045f42023-08-23T23:33:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.12440901244090Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative reviewHarrison D. Collier-Bain0Frankie F. Brown1Frankie F. Brown2Adam J. Causer3Annabelle Emery4Rebecca Oliver5Rebecca Oliver6Sally Moore7James Murray8James E. Turner9James E. Turner10John P. Campbell11Department for Health, University of Bath, Bath, United KingdomDepartment for Health, University of Bath, Bath, United KingdomSchool of Applied Sciences, Edinburgh Napier University, Edinburgh, United KingdomDepartment for Health, University of Bath, Bath, United KingdomDepartment for Health, University of Bath, Bath, United KingdomDepartment for Health, University of Bath, Bath, United KingdomDepartment of Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, United KingdomDepartment of Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, United KingdomDepartment of Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, United KingdomDepartment for Health, University of Bath, Bath, United KingdomSchool of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United KingdomDepartment for Health, University of Bath, Bath, United KingdomTherapeutic monoclonal antibodies (mAbs) are standard care for many B-cell haematological cancers. The modes of action for these mAbs include: induction of cancer cell lysis by activating Fcγ-receptors on innate immune cells; opsonising target cells for antibody-dependent cellular cytotoxicity or phagocytosis, and/or triggering the classical complement pathway; the simultaneous binding of cancer cells with T-cells to create an immune synapse and activate perforin-mediated T-cell cytotoxicity against cancer cells; blockade of immune checkpoints to facilitate T-cell cytotoxicity against immunogenic cancer cell clones; and direct delivery of cytotoxic agents via internalisation of mAbs by target cells. While treatment regimens comprising mAb therapy can lead to durable anti-cancer responses, disease relapse is common due to failure of mAb therapy to eradicate minimal residual disease. Factors that limit mAb efficacy include: suboptimal effector cell frequencies, overt immune exhaustion and/or immune anergy, and survival of diffusely spread tumour cells in different stromal niches. In this review, we discuss how immunomodulatory changes arising from exposure to structured bouts of acute exercise might improve mAb treatment efficacy by augmenting (i) antibody-dependent cellular cytotoxicity, (ii) antibody-dependent cellular phagocytosis, (iii) complement-dependent cytotoxicity, (iv) T-cell cytotoxicity, and (v) direct delivery of cytotoxic agents.https://www.frontiersin.org/articles/10.3389/fonc.2023.1244090/fullexercisecancer therapynatural killer cellsphagocytescomplement proteinsT-cells |
| spellingShingle | Harrison D. Collier-Bain Frankie F. Brown Frankie F. Brown Adam J. Causer Annabelle Emery Rebecca Oliver Rebecca Oliver Sally Moore James Murray James E. Turner James E. Turner John P. Campbell Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review Frontiers in Oncology exercise cancer therapy natural killer cells phagocytes complement proteins T-cells |
| title | Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review |
| title_full | Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review |
| title_fullStr | Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review |
| title_full_unstemmed | Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review |
| title_short | Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review |
| title_sort | harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against b cell haematological cancers a narrative review |
| topic | exercise cancer therapy natural killer cells phagocytes complement proteins T-cells |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1244090/full |
| work_keys_str_mv | AT harrisondcollierbain harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT frankiefbrown harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT frankiefbrown harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT adamjcauser harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT annabelleemery harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT rebeccaoliver harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT rebeccaoliver harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT sallymoore harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT jamesmurray harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT jameseturner harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT jameseturner harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview AT johnpcampbell harnessingtheimmunomodulatoryeffectsofexercisetoenhancetheefficacyofmonoclonalantibodytherapiesagainstbcellhaematologicalcancersanarrativereview |